Oral Fluoroquinolone and the Risk of Aortic Dissection

Previous studies raised safety concerns on the association between fluoroquinolone treatment and serious collagen disorders, aortic aneurysm and dissection (AA/AD). This study sought to evaluate this association via a case-crossover analysis in a large national administrative database. A case-crosso...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2018-09, Vol.72 (12), p.1369-1378
Main Authors: Lee, Chien-Chang, Lee, Meng-tse Gabriel, Hsieh, Ronan, Porta, Lorenzo, Lee, Wan-Chien, Lee, Si-Huei, Chang, Shy-Shin
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Aneurysm, Dissecting - epidemiology
Anti-Bacterial Agents - adverse effects
Antibiotics
aortic and arterial diseases
aortic aneurysm
Aortic Aneurysm - epidemiology
Aortic aneurysms
Aortic dissection
Bias
Cardiology
Collagen
Collagen (type I)
Confidence intervals
Congenital diseases
Cross-Over Studies
Crossovers
Databases, Factual
Defects
Disease control
Dissection
Exposure
Extracellular matrix
Family medical history
Female
Fluoroquinolones
Fluoroquinolones - adverse effects
Health hazards
Health insurance
Health risks
Humans
Hypertension
Logistic Models
Male
Medical imaging
Medical research
Older people
Patients
Population
Research methodology
Risk management
Sensitivity analysis
Statistical analysis
Studies
Taiwan - epidemiology
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies raised safety concerns on the association between fluoroquinolone treatment and serious collagen disorders, aortic aneurysm and dissection (AA/AD). This study sought to evaluate this association via a case-crossover analysis in a large national administrative database. A case-crossover design was used to compare the distributions of fluoroquinolone exposure for the same patient across a 60-day period before the AA/AD event (hazard period) and 1 randomly selected 60-day period (referent period) between 60 to 180 days before the AA/AD events. In the sensitivity analysis, the authors repeated the main analysis using a 1:5 ratio of hazard period to referent period, to adjust for the effect of time-variant confounders. A disease-risk score–matched time control analysis was performed to investigate the potential time-trend bias. The risks were calculated by a conditional logistic regression model. A total of 1,213 hospitalized AA/AD patients were identified between 2001 and 2011. In the main case-crossover analysis, exposure to fluoroquinolone was more frequent during the hazard periods than during the referent periods (1.6% vs. 0.6%; odds ratio [OR]: 2.71; 95% confidence interval [CI]: 1.14 to 6.46). In the sensitivity analysis, after adjustment for infections and co-medications, the risk remains significant (OR: 2.05; 95% CI: 1.13 to 3.71). An increased risk of AA/AD was observed for prolonged exposure to fluoroquinolones (OR: 2.41 for 3- to 14-day exposure; OR: 2.83 for >14-day exposure). Susceptible period analysis revealed that the use of fluoroquinolone within 60 days was associated with the highest risk of AA/AD. In the case-time-control analysis, there was no evidence that the observed association is due to temporal changes in fluoroquinolone exposure. Exposure to fluoroquinolone was substantially associated with AA/AD. This risk was modified by the duration of fluoroquinolone use and the length of the hazard period. [Display omitted]
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2018.06.067